šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX Ā· Real-Time Price Ā· USD
5.14
+0.91 (21.51%)
Nov 18, 2026, 12:13 PM EST - Market open
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 10, 2026

Summary

The PV study will test dose response and hematocrit control, with initial readouts planned from Q1 2027. Three phase II programs are expected to report in 2027, while $80 million in cash was projected to fund execution into 2029.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

All right, we're going to go ahead and get started. I'm Steve. We are on the dosing curve in PV patients. We know what that looks like extensively in non-PV patients over long periods of time. We'll start at a 250 mg once a day oral, very simple.

Patients start, these are phlebotomy control patients, so they start below 45% hematocrit, and our aim here is just to keep them there. They're having multiple phlebotomies once a month, once every other month. We want to be able to maintain their hematocrits below 45%. That part is you can start at a dose. If you need a little more, then you can step up after a month to the next higher dose, 500 mg, and then 750 mg after that. We think we'll find the dose within that. 250 mg may be perfectly fine for most patients, or they may need a little more. We don't know. Then we'll analyze that data. The main purpose of that part one is just to see, do all these observational data that we see, does that translate into PV?

Do we have a drug here?

What's the dose? Then we go into a part two where we randomize patients. They stay on their dose or they go to placebo and see if it returns to baseline if they're on placebo. We incorporate PROs on how they're feeling when they go off drug. There'll just be more convincing data, but not necessary for a phase III design that we have. Then there's an extension, part three, that we would have after that.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

That gives you durability data.

Stephen Willey
Managing Director, Stifel

So it sounds like these are patients who have hematocrit sub 45, some baseline level of phlebotomies. It kind of sounds like this is going to look like a lot of the other proof of concept phase II trials that we've seen—

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yes

Stephen Willey
Managing Director, Stifel

—in this space. From an efficacy benchmarking perspective, this should give you a pretty clear answer, correct?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. Yeah, I think so.

Stephen Willey
Managing Director, Stifel

Okay. How are you thinking just about the cadence of data disclosures that we should expect to see from this trial throughout the course of next year? Maybe you can also speak to kind of the amount and the type of data that we should expect to see with kind of maybe the first couple of disclosures.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We are planning to start the first patient dose this year. We think that around the first quarter, we should have that first 10 patients sentinel through month one and be able to read that out. But then those same patients are going to start rolling into part one, and around mid-year, they will be at the 28-week or so timeframe. We think that there's potential, once we have enough patients out long enough that we can say that we're reducing phlebotomies or holding patients' hematocrit, then we'd have a data cut. We look at some of the competitive programs like rusfertide.

The announced date after seven patients. They had patients between 28 weeks and four weeks. Somewhere in the 10-15 patient range over a course of time, we'll do a data cut. We want to get this out to the markets and to us. It's an open-label trial, so we're going to know what's going on and get these data. Then we'll have just kind of a sequence of data cuts over time, whether we present at ASH or some of these conferences, things like that.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Mid-year to third quarter, I think we'll start having, like, does this drug work in PV like it's intended?

Stephen Willey
Managing Director, Stifel

Okay. Yeah, PV has become a very active development landscape. You mentioned rusfertide that just received FDA approval. There's a number of other hepcidin-modulating therapies that are, I guess, entering late-stage development, and one of which was just the focal point of a fairly sizable M&A transaction. How do you think about the opportunity to establish competitive differentiation with the epetraborole relative to some of those other therapies that are in phase II?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah, I think first and foremost, from what we hear back from key opinion leaders and so forth is, epetraborole is oral, so all those therapies are injectable, number one. Two is, it's a different mechanism of action. We know, kind of the effect occurs in late-stage erythrocytes, but we think it's on the globin side, and all those agents affect iron starvation and kind of the heme side of the equation. So it's a different MOA, which allows you opportunities to look at combinations or different things to control hematocrit. Three is, it seems to be exquisitely red blood cell focused, so it doesn't have much effect on platelets, it doesn't have any effect on white blood cells or precursors, so it seems to be red cell specific, which is highly desirable.

If all those things happen, I think it seems like it's got a very broad use case relative to some of those agents.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

Yeah, I think some of the leukocytosis and thrombocytosis we've seen with those drugs is still kind of an interesting work in progress.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah

Stephen Willey
Managing Director, Stifel

In terms of what that means clinically. I guess if everything works out in phase II, would you expect to be in a position to initiate a registrational development program in 2028? And then we've seen a lot of the contemporary trials accommodate background cytoreductive therapy. Would you have to accommodate rusfertide as background therapy?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah, I don't think so. I think the current trial is going to allow cytoreductive agents.

Hydroxyurea is commonly used, for example. Patients aren't—25% of patients are controlled by it, roughly, and patients can be on that therapy. Is there a case for adding it to rusfertide? Yeah, maybe down the road, but I think ideally patients don't want to inject, so they're going to want an oral therapy first. But if they're difficult to control, and you can put two agents, but I think that's more of a minority case in the future.

Stephen Willey
Managing Director, Stifel

Okay. The epetraborole is also in another phase II trial. This is, I think it's an investigator-sponsored study.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

This is in Mycobacterium abscessus. Can you just speak to how this opportunity was informed by the prior trial in NTM MAC, and maybe also talk about how abscessus clinically differentiates from MAC?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We ran a phase II/III trial in MAC in what I would say is probably severely treatment refractory patients on every measure. We really were following Insmed's ARISE case, had run a trial in this population. But in terms of years of disease, we had three times the years of disease, lots of multidrug resistance, and lots of cavitary, fiber cavitary involvement in the patients. In hindsight, I think we realized kind of the postmortem that patient population, no single drug added to a failing regimen is going to turn those patients around.

We looked at, and for our data with abscessus, we have the strongest biological data. It is 250 times more potent than MAC, epetraborole is. The PK/PD, both of them had good PK/PD drivers, but sometimes in these severe patients, you get both intracellular and extracellular. It does not matter when you are so potent. We have less exposure extracellular than in macrophages. We looked at all the PK/PD, and we had just a strong scientific case for abscessus. It also happens to be the most unmet of needs. There is no FDA-approved drug. Patients currently have to go on multiple IV daily therapies, like amikacin-imipenem. It is like chemotherapy.

It is a daunting task to ask patients to be on that for months and months at a time. So, having an oral therapy to that. The KOL community that is involved in this study, we have about 15 sites, academic sites that are all the top KOLs, were super excited about the potential of this drug in abscessus. I also just quickly mention that Paratek had a successful study in treatment-naive abscessus, and our drug in preclinical models run by the same investigator is cidal, theirs is static. So there was a lot of potential there too. Anyway, we are very optimistic for that. In the U.S., it is 15,000 patients, and your backbone therapy on all of those could be a very attractive market for us.

Stephen Willey
Managing Director, Stifel

Okay. I know you are guiding to a top-line disclosure from this abscessus study next year. Is that correct?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yes. Yeah.

Stephen Willey
Managing Director, Stifel

I know you're looking at a number of clinical endpoints. Is there a threshold improvement in either culture conversion or PRO-based symptoms that you either need or want to see in order to be confident about taking that next step and going into registration? Then you talked about the Paratek drug. How do you think about that phase II data as just kind of a clinical efficacy benchmark?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. They showed about a 20-point improvement in culture conversion. We think, this is an antibacterial, so we think you've got to clear bacteria from the lungs.

That's destroying the lung and creating these high five-year mortality rates in these patients. So, bacteria culture conversion, we think, is super important. To the FDA, it's feels, functions, and survives. We think we're going to need to show an improvement in PRO on feels, so like quality of life, the respiratory scale that's been used. We developed our own MACO-2. We're looking at a number of scales in this IIT/phase II trial. But we'll have some component of that ultimately for a phase III trial.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

Would you anticipate having to do any validation work on a PRO prior to initiating a phase III?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We validated it in our—

Stephen Willey
Managing Director, Stifel

Okay

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

—prior MAC study, but we will run through that same routine for the abscessus. Yeah.

Stephen Willey
Managing Director, Stifel

Okay. You mentioned about 15,000 patients in the U.S. How do you think about the opportunity to potentially harmonize pricing between PV and abscessus? As you think about PV potentially being kind of a strategically active landscape right now, how do you think about the flexibility of having this drug in kind of two disparate separate indications right now?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. It is interesting. I think they are both rare orphan diseases. From a pricing point of view, they are going to end up being very similar, we believe, is precedented by ORKAMBI and nusinersen, for that matter. They are similar in that. I think it is a good. We hope it works in both of these. That is a good problem to have.

Ideally, we will have a partner that could take both forward. We will figure that out.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

To us, it is a good problem to anticipate.

Stephen Willey
Managing Director, Stifel

Okay. Maybe staying on the anti-infective track here, I know you have another phase II-ready asset. This is an anti-parasitic.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

It is directed against a target that is relevant in the onset of Chagas disease. I think this Chagas story, to me, actually is kind of pretty fascinating, just given the epidemiological relevance of this. There is a lot of parallels that you can draw to hepatitis C. Can you just kind of give us the quick elevator pitch on Chagas and why you think investors should be paying attention to this?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. This is what attracted me. My passion is global health, and there are 10 million patients that have parasites in their heart, and we do not have an effective drug for them. That bothers me. It probably bothers everybody. It happens to be that 300,000 plus live in the U.S. We have a drug that we have shown to sterilize non-human primates that naturally get infected in the state of Texas by the kissing bug. Same organism, same pathway to infection. They are natural carriers. We have greatly de-risked this program as much as you could possibly de-risk a program, I think, at this point. We think that there is a dual market. It happens to be, you mentioned hepatitis C. Hepatitis C is a silent killer.

There are no symptoms until you start having liver failure, liver cancer, and things like, in about 30% of patients. With Chagas, you get the same thing with heart disease. About 30% of patients develop heart failure and so forth. Or you drop dead, so they end up in a cardiologist's office. We think that this is very much like a smaller version of the hepatitis market that we think is as big as $30 billion in the U.S.

If you treated every single patient available. That is a big opportunity, but most importantly, it is an opportunity for us to help patients who have suffered from this. I mean, the millions of patients that do. That is the pitch, and we think it is a fairly easy scientific de-risk program.

Stephen Willey
Managing Director, Stifel

Okay. Is there an active screening program for Chagas in the U.S.? Are neonates screened or blood banks screened?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah, it is transmitted from mother to child, I mean, which is horrible, but it's not routinely done. It's rarely done screening. There's a few passionate academics who have screened. There's a couple physicians in Boston who screened 25,000 patients, but it's really a passionate group in one area and another. That will be part of the ultimate implementation, is to screen everybody, just like you do with HCV, like you do with HIV. So it's basically test and treat.

Stephen Willey
Managing Director, Stifel

Okay. And so that top-line phase II data for Chagas, we're expecting that in the second—

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Second half

Stephen Willey
Managing Director, Stifel

—half of next year. What does that disclosure look like?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

It's basically going to show parasite clearance—

Stephen Willey
Managing Director, Stifel

Okay

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

—and what we believe is tested, like a curative profile. We will be measuring parasitology, serology, and showing that data.

Stephen Willey
Managing Director, Stifel

Is there a duration of follow-up?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah, we, based on all these monkey studies we've done, four months is very predictive.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

We think that's fairly doable in a short period of time. We can enroll this trial quickly because we're going to run it in Bolivia, where 8% of Bolivians have Chagas.

It's easy to find patients. Four months, but we'll follow the phase II patients for a year and basically validate that, and then just run a larger version of that for phase III.

Stephen Willey
Managing Director, Stifel

But I guess when you disclose the data, do you want to have four months of follow-up—

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah

Stephen Willey
Managing Director, Stifel

—on all patients?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

That's right.

Stephen Willey
Managing Director, Stifel

Okay. And so that four months of follow-up in Chagas, I guess, would be analogous, keeping with the hepatitis C parallel to like SVR12.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

Okay. So I guess hepatitis C in kind of keeping with the parallel here, right? I mean, that kind of became the multi-billion dollar opportunity it did because there was a big implementation effort on the diagnostic and awareness front. As you think about that heavy lift that is necessary to transform this market, is this a program that kind of at the end of the day is maybe best served or better served by a larger company kind of with the resources and bandwidth to rerun that playbook?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Could very well be. I mean, in this space, we've seen Merck had a program, Eisai, the Japanese companies had programs. J&J's been interested, GSK. We think there's a number of strategics that are interested in this area.

Stephen Willey
Managing Director, Stifel

Okay. This is not the first anti-parasitic drug that you've developed. Ironically, I believe this goes after the same target as the prior anti-parasitic that you had developed. Maybe you could talk about that a little bit.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We helped co-discover a drug called acoziborole, which was approved earlier this year for another trypanosome disease called African sleeping sickness. It's the same mechanism of action as that drug that was proved to be 96% curative in a phase III pivotal study as a single-dose cure for a fatal parasitic disease in the brain. That's the African trypanosomiasis, and Chagas disease is the American version of that.

That affects a lot more people. That was approved by the EMA with outstanding efficacy, and it also highlights, I mean, as an aside, our boron chemistry is able to engage targets. CPSF3 has never been in another human drug, and so it shows the potential of our chemistry to hit novel targets.

Stephen Willey
Managing Director, Stifel

Okay. You also have an active preclinical pipeline. I know you have dual-track programs targeting ENPP1 for both oncologic and rare disease applications. Can you maybe just talk about the relevancy of this target in both of those disease states, and how has that informed kind of your tailoring of development candidates for each application specifically?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We were interesting. We followed biology, so we were working on viral targets and realized that this ENPP1 was very similar, and it had applications in oncology. It basically turns cold tumors hot, essentially, and allows the immune system to recognize and treat them. So we went after that. We have made hundreds, like on the order of 800 compounds. Boron is very It is a perfect target for boron and one of the eight binding modes that we know of. So we were interested in that, and as it turned out then, this rare bone disorder, HPP, application came around. So ENPP1 is directly engaged in hypophosphatasia and provides an oral route to target that disease instead of an enzymatic replacement like Alexion, AZ's Strensiq, that has been highly successful, that is injectable.

So, we just announced last week that we have developed a candidate for HPP and are advancing that rapidly.

It is exciting because BioMarin just bought Alesta and really has put this target on the map as an oral treatment potential for HPP patients. So we are super excited about that. But because boron is a great compound for this target, we made 800 compounds. We really optimize for an exquisitely potent, clean compound, so we were highly selective in doing that, versus lots of compounds in the space were developed for oncology quickly, and the bar is different for oncology than when you are treating small children and for lifetime on an HPP drug. So we were highly selective, I would say, in terms of finding compounds that had good drug-like properties.

PK permeability, off-target effects, minimizing all those, and could be selective. So we think we have a best-in-class profile around HPP. On the oncology side, where we started, we discovered a compound, we have run lots of animal models, it looks great, declared a candidate, but what the question there is, it is an unvalidated human target, and there were two companies in front of us in the clinic, so we thought, "Let us wait. Let us keep our resources on all the other programs and wait and see." But Riboscience is one of those companies at ESMO, just announced some very exciting data in colorectal cancer with metastasis in liver, that was showing some pretty promising data in terms of survival out to 14 months compared to four months for background.

Stephen Willey
Managing Director, Stifel

Yeah.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

We are super excited if that happens. We are sitting in a great position to really move forward. ENPP1 is just one. We have a PI3K program. We acquired another boron company that came out of Anacor, and they had a PI3K, and the more we have learned about that program, there is not really a true pan-mutant over wild-type PI3K. There is Relay, which is kinase-specific but does not really hit helical . Novartis just bought Synnovation, which I think is this kind of, to us, the third-generation compound, and that is more the profile we are going after. We think there is plenty of room, plenty of buyers that have breast cancer franchises that want one of those. We have that, and we have got a lot going on, as you can tell from this—

Stephen Willey
Managing Director, Stifel

Yeah

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

—conversation.

Stephen Willey
Managing Director, Stifel

Yeah, I was going to ask you, I guess, on the PI3K front, I think a lot of investors just from a 1,000-foot view believe that this is a pretty crowded space. You obviously

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

For sure

Stephen Willey
Managing Director, Stifel

I feel like there's still an opportunity for differentiation. I think maybe despite some of the BD activity that we've seen, whether it's Novartis Synnovation or Lilly Scorpion, you get the sense that there's still a lot of strategic appetite here?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Lots. Getting AL, again, this is an area that we moved into a little over a year ago, and to be honest, we didn't understand it that well. There was a lot of deals happening with Loxo and Scorpion and so forth. But as I said, most of those compounds were kinase-specific PI3Ks.

Relay shows beautifully that you have They can hit that, but the activity against helical , which makes up more than half of the patients, they don't get all the hyperglycemia, so patients can stay on it, but still the survival is low. It's like six, seven months. We think with a true pan-mutant where you have big separations between wild type and you hit these mutants much more potently, you can really increase progression-free survival. Synnovation, OnKure may have a compound. There's not many of them.

It's a very difficult thing to do to be able to bring in helical . That's what we're working on.

Stephen Willey
Managing Director, Stifel

Okay.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

The other thing I should say is boron also, it's a crowded IP space, as you say, and so boron is unique, so there's no freedom to operate issues or things like that. So it's clean from that, which is advantageous.

Stephen Willey
Managing Director, Stifel

Yeah, that's a really good point.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah.

Stephen Willey
Managing Director, Stifel

We just kind of talked through a lot of the milestones that you're expecting over the course of the next year or so. Can you just talk about the current cash that you have on hand and kind of what that allows you to execute on going forward?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Yeah. We're a very capital-efficient company. We have $80 million in cash that gets us into 2029 and execute on these programs. So we've got three phase IIs that we're going to read out next year, so we have cash to take all those through that. And we have our preclinical programs that we're advancing as well. So we think there's multiple ways to add value and win and get us into 2029. And so we have plenty of cash to do that.

Stephen Willey
Managing Director, Stifel

Okay. Anything we didn't talk about that you'd like to quickly highlight before we wrap it up?

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

No. I think people are just now learning, I think, about our PV program and realize that we have these other major clinical readouts in areas that they may not often think about, but have significant upside opportunity for us and risk mitigation. So we now have a really robust pipeline, and I don't think we've ever been stronger as a company now that we've matured and allowed the pipeline to mature. So super excited about this coming year for AN2.

Stephen Willey
Managing Director, Stifel

All right. Eric, thank you very much. Appreciate it.

Eric Easom
Co-Founder, President, CEO, and Chair, AN2 Therapeutics

Thank you, Steve.

Stephen Willey
Managing Director, Stifel

Thanks, everyone. All right.